Skip to main content

SAfety of Regional Citrate Anticoagulation (SARCA Study)

Completed · Phase 3 · NCT05339139

Conditions: Acute Kidney Injury, ESRD

At a glance

Research payments reported, 2025
$738,094
U.S. investigators named
10
Sites paid
10
Planned or actual enrollment
32

About the trial

Sponsor
Fresenius Medical Care North America
Tested
Dialysis (combination_product)
Dates
Started 2023-10-17; completion 2025-06-30
Results posted
Not yet

This is an Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO system in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study).

From ClinicalTrials.gov, last updated 2026-09-11. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Fresenius USA Marketing, Inc. reported $738,094 in research payments for this study in 2025 (67 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.